Cytori Therapeutics Inc (CYTX) : During the past 4 weeks, traders have been relatively bearish on Cytori Therapeutics Inc (CYTX), hence the stock is down -5.33% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -4.47% relative to the S&P 500. The 4-week change in the price of the stock is -5.53% and the stock has fallen -5.09% in the past 1 week.
For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 2.47% and the fifty day Moving Average is 0.56%. Cytori Therapeutics, Inc. has dropped 30.74% during the last three month period . Year-to-Date the stock performance stands at -28.07%.
Cytori Therapeutics Inc (CYTX) : The highest level Cytori Therapeutics Inc (CYTX) is projected to reach is $11 for the short term and the lowest estimate is at $5. The consolidated price target from 2 rating analysts who initiate coverage on the stock is $8 and the possibility the share price can swing is $4.24.
Cytori Therapeutics Inc (NASDAQ:CYTX): stock turned positive on Friday. Though the stock opened at $2.01, the bulls momentum made the stock top out at $2.05 level for the day. The stock recorded a low of $2 and closed the trading day at $2.05, in the green by 0.99%. The total traded volume for the day was 62,705. The stock had closed at $2.03 in the previous days trading.
Cytori Therapeutics, Inc. (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns combined with radiation injury. The Company commercializes the Celution System under select medical device approvals, clearances and registrations to research customers developing new therapeutic applications for Cytori Cell Therapy in Europe, Japan and other regions. The Company offers ECCO-50, a cure for knee osteoarthritis, which is in ECCO-50 Phase IIA/B of development. It offers ECCI-50, a cure for urinary incontinence, which is in Phase II/III of development. The Company is also developing DCCT-10, a cure for cutaneous thermal injury.